Bio-Techne has partnered with Kantaro Biosciences, a joint venture of Mount Sinai Health System with Renalytix AI, to deliver Covid-19 antibody test kits.

The partners will develop, manufacture, sell and distribute testing kits based on the Mount Sinai-developed Covid-19 serology test.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the step, Bio-Techne and Kantaro Biosciences aim to enable the laboratories to conduct more than ten million tests in July and further increase the capabilities in the subsequent months.

The Kantaro’s IgG antibody test kit is an enzyme-linked immunosorbent assay designed to identify the presence of anti-Covid-19 antibodies. It also measures the titer (level) of antibodies that a person has produced.

The test kit uses two virus antigens, the full-length spike protein and its receptor-binding domain, necessary for viral entry into cells.

Bio-Techne and Kantaro Biosciences have also formed a joint commercialisation and distribution team to enable rapid distribution of the assay.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bio-Techne president and CEO Chuck Kummeth said: “We are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for Covid-19.

“The Bio-Techne, Mount Sinai and Kantaro teams are working around the clock to develop this test and we are on track to achieve in approximately eight weeks what would typically take 18 months or more.

“As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation’s needs. We look forward to providing the world with critical information related to past exposure to the virus.”